ABO DIAG has been acquired by DIAGAST
The private shareholders and investment funds Succes Eur. and Aqui Invest, based in France, have sold ABO DIAG to DIAGAST for US$6.5 million.
ABO DIAG was founded in 2008 by its CEO, Najim Chaibi. Located in the technopolis of Montesquieu, the company is based on the research and development of diagnostic devices dedicated to blood transfusion and more widely to immuno-haematology. ABO DIAG is a pioneer in the field of research of new solutions for haematological diagnosis. The company's patent protected technology is based on immunological detection in vertical flow with colored dots. This innovation provides higher sensibility and higher safety in diagnosis, thanks to a simple user procedure and with standardized results. ABO DIAG was awarded the First Prize of Innovation at JIB 2012 (Innovation of the year in Biology).
DIAGAST is the worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions. Over the last 30 years, the company has developed unparalleled expertise and know-how in the transfusion sector.
Oaklins' team in France advised the seller in this transaction.
Talk to the deal team
Related deals
Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn moreHe-Man Dual Controls has been acquired by Lagercrantz UK Limited
Lagercrantz UK Limited has acquired 100% of the shares in HM Holding Limited (He-Man Dual Controls), a leader in supplemental control systems for vehicles.
Learn moreManolete Partners plc has completed a successful debt refinancing
Manolete Partners plc has signed a new revolving credit facility (RCF) with its existing provider, HSBC. The new RCF provides Manolete with the same level of facility as the previous arrangement, at US$22.6 million (£17.5 million), but with a reduced margin and lower non-utilization fee. The facility has a term of 3.25 years, with the option to extend for an additional year on the same terms.
Learn more